Generalized Anxiety Disorder

Detailed Overview

Unlike panic disorder, which involves acute bursts of terror, GAD involves a pervasive state of 'free-floating' anxiety. Patients find it incredibly difficult to control the worry. This psychological state is coupled with somatic symptoms such as muscle tension, fatigue, and sleep disturbances. GAD is highly comorbid with Major Depressive Disorder and other anxiety disorders. It follows a chronic, fluctuating course, often worsening during periods of psychosocial stress.

Epidemiology & Demographics

Lifetime prevalence is approximately 5-6% in the United States. It is twice as common in women as in men. Onset usually occurs in early adulthood, but many patients report having been 'anxious all their life.'

Etiological Mechanism

The etiology is multifactorial, involving a combination of genetic predisposition (heritability is ~30%), neurobiological imbalances, and environmental stressors.

Primary Causes

Genetic Predisposition

Altered Brain Chemistry (Serotonin, GABA, Norepinephrine imbalances)

Environmental Stressors (Childhood trauma, chronic stress)

• Family History: Having a first-degree relative with GAD or depression increases risk.
• Female Sex: Women are diagnosed at double the rate of men.
• Childhood Adversity: History of physical/emotional abuse or significant early loss.
• Chronic Medical Illness: Conditions like thyroid disease or chronic pain can precipitate GAD.

Neurobiologically, GAD is associated with hyperactivity of the amygdala, the brain region responsible for processing fear and threatening stimuli. There is also reduced connectivity between the amygdala and the prefrontal cortex, leading to a failure of top-down inhibitory control over the fear response. Neurotransmitter imbalances play a key role: decreased inhibitory signaling of GABA, and dysregulation of serotonin (5-HT) and norepinephrine. The autonomic nervous system is chronically in a mild state of hyperarousal.

Characteristic Clinical Presentation

• Excessive Worry: Persistent, disproportionate worry about multiple domains that the patient cannot control.
• Restlessness: Feeling keyed up or on edge.
• Fatigue: Easily fatigued due to chronic muscle tension and hyperarousal.
• Muscle Tension: Often manifesting as headaches, jaw pain, or neck/shoulder aches.
• Sleep Disturbances: Difficulty falling asleep or staying asleep, leading to non-restorative sleep.

Physical Examination Signs

• Restless movements, pacing, or fidgeting during the exam.
• Tachycardia or mild tachypnea without physical exertion.
• Palpable muscle tension in the cervical or trapezius muscles.

• Major Depressive Disorder: Highly comorbid; untreated GAD frequently leads to clinical depression.
• Substance Abuse: Patients often self-medicate with alcohol or benzodiazepines.
• Cardiovascular Issues: Chronic autonomic arousal is linked to increased risk of hypertension and coronary artery disease.

Diagnostic Criteria & Guidelines

DSM-5 Criteria: Excessive anxiety and worry occurring more days than not for at least 6 months, about a number of events. The worry is difficult to control. Associated with 3 or more of the following 6 symptoms: restlessness, easily fatigued, difficulty concentrating, irritability, muscle tension, sleep disturbance. (Only 1 item is required for children).

Differential Diagnosis

• Hyperthyroidism
• Panic Disorder
• Substance-Induced Anxiety (e.g., Caffeine intoxication, stimulant withdrawal)
• Major Depressive Disorder

Laboratory Tests & Biomarkers

• Thyroid Stimulating Hormone (TSH): Should be normal. Ordered to rule out hyperthyroidism.
• Urine Drug Screen: To rule out stimulant abuse.

Imaging Modalities & Findings

• None routine:

• Mild
  Symptoms present but manageable; minimal interference with daily functioning.
• Moderate
  Symptoms cause significant distress and noticeable functional impairment.
• Severe
  Incapacitating anxiety, severe somatic symptoms, complete functional impairment.

Second-Line & Adjunctive Therapy

Buspirone (10-30 mg BID), a 5-HT1A partial agonist. Pregabalin (75-300 mg BID) where approved. Benzodiazepines (e.g., Clonazepam 0.25-0.5 mg BID) only for short-term bridge therapy (2-4 weeks) while waiting for SSRIs to take effect, due to addiction risk.

Surgical & Procedural Management

None.

Recommended Lifestyle Changes

• Strict elimination of caffeine and illicit stimulants.
• Regular cardiovascular exercise, which has proven efficacy comparable to medication in mild GAD.
• Mindfulness-based stress reduction and progressive muscle relaxation techniques.

Patient Counseling & Advice

Inform the patient that SSRIs take 4-6 weeks to reach full efficacy and may initially cause mild nausea or slightly increase anxiety in the first few days. Stress that therapy (CBT) is about learning tools to manage the worry, not necessarily eliminating all stress from life.

Follow-Up & Monitoring Schedule

Reassess every 2-4 weeks initially to monitor for medication side effects, specifically checking for emerging suicidal ideation (especially in young adults) or worsening anxiety. Once stable, assess every 3-6 months.

Preventive Strategies

Early intervention with therapy during adolescence if anxiety traits are prominent. Stress management training.

GAD is generally a chronic, lifelong condition with periods of exacerbation and remission. With optimal combination treatment (CBT + SSRI), up to 50-60% of patients achieve significant remission.